Glenmark Pharmaceuticals Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Capsules USP, 15 mg and 25 mg. Glenmark's Topiramate Capsules USP, 15 mg and 25 mg has been determined by the FDA to be bioequivalent and therapeutically equivalent1 to Topamax®2 Capsules, 15 mg and 25 mg of Janssen Pharmaceuticals, Inc., and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIATM sales data for the 12-month period ending May 2024, the Topamax® Capsules, 15 mg and 25 mg market achieved annual sales of approximately $21.9 million.

Powered by Capital Market - Live News

The approved drug is bioequivalent and therapeutically equivalent to Topamax capsules of Janssen Pharmaceuticals and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

Topiramate is used alone or with other medications to treat certain types of seizures including primary generalized tonic-clonic seizures and partial onset seizures. It is also used with other medications to control seizures in people who have Lennox-Gastaut syndrome (a disorder that causes seizures and developmental delays) as well as to prevent migraine headaches but not to relieve the pain of migraine headaches when they occur in adults and children 12 years of age and older.

According to IQVIA, the Topamax Capsules market achieved annual sales of approximately $21.9 million sales for the 12-month period ending May 2024.

Glenmark's current portfolio consists of 198 products authorized for distribution in the U.S. marketplace and 50 ANDA's pending approval with the U.S. FDA.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses.

Glenmark Pharmaceuticals reported net loss of Rs 1,238.64 crore in Q4 FY24 as compared with net loss of Rs 549.49 crore in Q4 FY23. Revenue from operations increased 1.94% to Rs 3,016.00 crore in Q4 FY24 as compared with Rs 2,958.36 crore in Q4 FY23.

The scrip rose 0.20% to end at Rs 1,410.50 on Tuesday, 16 July 2024. The market is closed today on account of Moharram.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 1344.75, up 3.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 24279.9. The Sensex is at 79810.25, down 0.3%. Glenmark Pharmaceuticals Ltd has added around 11.15% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 6.43% in last one month and is currently quoting at 20192.6, up 1.37% on the day. The volume in the stock stood at 8.95 lakh shares today, compared to the daily average of 6.89 lakh shares in last one month.

The benchmark July futures contract for the stock is quoting at Rs 1348.5, up 3.78% on the day. Glenmark Pharmaceuticals Ltd is up 101.23% in last one year as compared to a 24.53% gain in NIFTY and a 47.56% gain in the Nifty Pharma index.

The PE of the stock is 25.66 based on TTM earnings ending March 24.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting at Rs 1251.5, up 0.7% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 23559.35. The Sensex is at 77463.83, up 0.21%. Glenmark Pharmaceuticals Ltd has added around 20.98% in last one month.

Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 2.68% in last one month and is currently quoting at 19826.65, down 0.54% on the day. The volume in the stock stood at 5.53 lakh shares today, compared to the daily average of 13.62 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1251.5, up 0.72% on the day. Glenmark Pharmaceuticals Ltd is up 94.38% in last one year as compared to a 25.2% gain in NIFTY and a 48.96% gain in the Nifty Pharma index.

The PE of the stock is 24.61 based on TTM earnings ending March 24.

Powered by Capital Market - Live News